News Archive

Retired Maj. Gen. Linda L. Singh, former adjutant general of the Maryland National Guard, has joined Towson University as its first leader-in-residence, the university announced Monday.

Retired Major General Linda Singh was just appointed as interim Executive Director/Chief Executive Officer (ED/CEO) for TEDCO as of January 2020.

Experimental Nanoformulation Outperforms FDA-Approved Treatment for Metastatic Breast Cancer, Increasing Survival in Animal Studies

The company is developing phage-based therapies designed to target specific bacteria strains, as contrasted with antibiotics, which target multiple types of bacteria.

Maryland Technology Development Corporation (TEDCO) is once again accepting applications from startups seeking investment from several of its funds that were put on hold in the middle of 2019.

The Maryland Technology Development Corp. and the National Institute of Standards and Technology awarded four companies a total of $448,000 to develop NIST-licensed technologies for the market, TEDCO announced Tuesday.

Project will support the increasing global need for “off-the-shelf” cell banks and hMSC bioprocess media products as sales continue to climb.

Hememics Biotechnologies Inc. plans to use the investment from AMVI Partners to begin clinical research for FDA submission for its flagship biotech product, a point-of-care panel to test for sexually transmitted diseases

'It was a life saver': New London developed device for feeding tube insertions is a world first

CSL Ventures, Blu Ventures, Texas Ventures and Texas Halo Fund lead investment in Machfu’s technology that securely connects critical assets and sensors to modern web services

This year, Yarina's company, Sisu Global, launched its first product designed to tackle the problem of chronic blood shortages for transfusions in certain parts of Africa. This device, called Hemafuse, can replace or augment donor blood in emergency situations. The company has won multiple awards

Hackensack Meridian Health has invested in the clinical-stage biotechnology company Adaptive Phage Therapeutics (APT), as part of the health network's successful innovation program, the Bear's Den.